Syntara Limited
ASX: SNT
Syntara narrows losses, boosts cash, and advances FDA milestones.
(Source: TradingView) 3-Month Performance Profile of SNT on a DTF compared to S&P/ASX 200 (XJO).
Syntara Limited’s H1 FY25 results showed progress on both operational and regulatory fronts. R&D and clinical trial costs remained the largest expenses, with trials accounting for about $2.63 million
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
